Head-to-head evidence
baricitinib vs ZL-82
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: JAK · full Atopic Dermatitis pipeline
baricitinib · Olumiant
Marketed by Eli Lilly
NCT03334396 · Phase 3 · completed
This was a large, randomized, double-blind, placebo-controlled trial of 660 participants. The primary clinical endpoint was met for both 2 mg and 4 mg baricitinib: 11.4% and 16.8% achieved the specified IGA response versus 4.8% with placebo, with statistically significant comparisons.
Next expected readout: May 2030 · NCT07262983 (registry estimate)
ZL-82
Developed by Chengdu Zenitar Biomedical Technology
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2027 · NCT07193589 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: baricitinib's landscape · ZL-82's landscape